CEO's large proposed sale (~$33.6M) signals potential insider distribution; monitor for actual Form 4 filings to confirm execution. The sale is concurrent with option exercise, suggesting a planned liquidity event rather than a distress signal, but the magnitude relative to market cap is notable. Watch for any subsequent insider selling patterns or changes in guidance.
PTGX drugs
PTGX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $148.29entry
- T+1 · 3mo ago +2.51%α +2.26% · $152.01
- T+5 · 3mo ago +6.10%α +6.51% · $157.34
- T+20 · 2mo ago −2.16%α −1.10% · $145.09
- T+60 · 13d ago −3.32%α −2.83% · $143.37
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Dinesh Patel filed a Form 144 notice of intent to sell 225,000 shares of Protagonist Therapeutics (PTGX) through J.P. Morgan Securities, with an estimated aggregate market value of approximately $33.6 million based on the filing date. This represents a large proposed sale relative to Patel's remaining holdings of ~64.7 million shares, but the CEO's intent to sell a meaningful stake signals potential insider distribution at a $9.4B market cap company.
Key Facts
- CEO Dinesh Patel filed Form 144 to sell 225,000 shares of PTGX common stock.
- Estimated aggregate market value of the proposed sale is $33,583,500.
- Patel holds approximately 64,708,285 shares after the proposed sale (post-sale holdings).
- The shares to be sold were acquired via option exercise on August 10, 2026.
- The sale is planned through J.P. Morgan Securities LLC as agent.
- The filing date is August 10, 2026; the proposed sale date is also August 10, 2026.
Financial Impact
CEO proposes to sell ~$33.6M worth of stock, representing ~0.35% of market cap and ~0.35% of his post-sale holdings.
Risk Factors
- CEO selling a large dollar amount could signal lack of confidence or need for liquidity.
- The sale may be executed quickly (same-day filing and proposed sale date), increasing near-term selling pressure.
- If the sale is completed, it could weigh on sentiment given the $9.4B market cap and 90% analyst bullishness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001968582-26-000805 |
| Document: 0001968582-26-000805-index.html | 0001968582-26-000805 |
| Document: 0001968582-26-000805.txt | 0001968582-26-000805 |
Track record
11 reports on PTGX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Viewing Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers